Clonidine Transdermal System Recall Over Manufacturing Issue
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Teva Pharmaceuticals USA, Inc. is recalling 62,136 cartons of Clonidine Transdermal System due to CGMP deviations involving the use of an unapproved raw material, affecting products distributed within the U.S.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on April 22, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action, a single localized FDA recall is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (recall, product-safety, fda, Drugs) map to related alerts in the same area of risk - browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
Clonidine Transdermal System Recall
What Happened
Teva Pharmaceuticals USA, Inc. is initiating a voluntary recall of Clonidine Transdermal System because of CGMP deviations, specifically the use of an unapproved raw material in the manufacturing process.
Which Products Are Affected
The affected product is Clonidine Transdermal System, USP, 0.2 mg/day, supplied in cartons of 4 Systems and 4 Adhesive Covers. It is identified by NDC codes such as 0591-3509-04 and 0591-3509-54, with lot numbers 100060002 (expiration 07/2026) and 100066802 (expiration 05/2027). A total of 62,136 cartons are involved, and the products were distributed within the U.S.
What You Should Do
Consumers who have the affected product should follow the initial firm notification, which was issued via letter, and contact Teva Pharmaceuticals USA, Inc. at their address: 400 Interpace Pkwy Bldg A, Parsippany, NJ 07054-1120, for instructions on returns or refunds related to recall number D-0473-2026.
Why This Matters
This recall highlights potential quality issues in prescription drugs, affecting over 62,000 cartons distributed in the United States and emphasizing the importance of adhering to manufacturing standards to ensure product safety.
Source
FDA recall notice for event ID 98614, available through the FDA website.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Frequently Asked Questions
Common questions about this FDA recall.